|
Acholic stool
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
The mean H-score for glypican-1 of mesothelioma (134 ± 59, mean ± SD) was not significantly different from that for pulmonary adenocarcinoma (156 ± 60; P = 0.21).
|
29785020 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Glypican-1 expression showed 100 sensitivity, 97% specificity, and a 98% accuracy rate to differentiate epithelioid mesothelioma from lung adenocarcinoma.
|
29327712 |
2018 |
|
Adenocarcinoma of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glypican-1 (GPC1) in exosomes has been identified as an early diagnostic biomarker for pancreatic adenocarcinoma.
|
29963198 |
2018 |
|
Albright's hereditary osteodystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
GPC1 and/or STK25 haploinsufficiency may also contribute to the AHO-like phenotype.
|
15521982 |
2004 |
|
Alkaline phosphatase raised
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
We conclude that Abeta can modulate the cellular expression of agrin and glypican-1, which may contribute to the accumulation of these HSPG in AD lesions.
|
19166823 |
2009 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
The results raise the possibility that glypican-1 interacts with oligomerized or polymerized Abeta in such a specific compartment as DIG, resulting not only in amyloid deposition in senile plaques of AD brain, but also in accelerating neuronal cell death in response to stress and Abeta.
|
15084524 |
2004 |
|
Ameloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Differences detected in glypican-1 expression among different subtypes of ameloblastomas, could be suggesting a possible association with their different biological behavior.
|
25046223 |
2015 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry of GPC1 expression in a tissue microarray of PDAC and various controls also did not demonstrate specificity of GPC1 to PDAC.
|
30800217 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
An aberrant overexpression of GPC1 protein which is usually absent in normal pancreatic duct, was a widespread marker across the full spectrum of human PDAC precursors, PDAC, and pancreatic cancerous stroma.
|
29245923 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
QRT-PCR demonstrated increased GPC1 mRNA levels in pancreatic ductal adenocarcinoma (PDAC) compared to normal pancreatic tissues (NPT), as described previously.
|
17016645 |
2006 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
Biomarker
|
disease |
BEFREE |
GPC1-positive bead percentages determined by flow cytometry were significantly higher in PDAC than in the control group.
|
31400579 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this initial validation study, the biomarkers glypican-1 and CD63 were found to reflect the presence of PDAC and thus were used to develop a bivariate model for detecting PDAC.
|
29570265 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
However, GPC1 levels were enriched in PDAC crExos (<i>n</i> = 11), compared to the source tumors (<i>n</i> = 11; 97 ± 54 vs. 20.9 ± 12.3 pg/mL; <i>P</i> < 0.001).
|
29721179 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that GPC1 mRNA was silenced in normal pancreata; however, it was re-expressed in PDAC tissues probably because of the promoter hypomethylation.
|
28440066 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Thus, our exosomal miR signature is superior to exosomal GPC1 or plasma CA 19-9 levels in establishing a diagnosis of PDAC and differentiating between PDAC and CP.
|
28232049 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic curve (ROC) analysis showed that serum CA19-9 was significantly better than serum GPC1 in distinguishing PDAC patients from the controls (AUC, 95% CI: 0.908, 0.868-0.947 vs 0.795, 0.749-0.841, respectively).
|
30358133 |
2018 |
|
Atretic gallbladder
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Benign Prostatic Hyperplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The use of MIL-38 to detect GPC-1 by IFA discriminated between prostate cancer and BPH urine specimens with a sensitivity and specificity of 71% and 76%, respectively.
|
29672570 |
2018 |
|
Bile duct proliferation
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Biliary Atresia
|
0.320 |
SusceptibilityMutation
|
disease |
ORPHANET |
Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility gene.
|
23336978 |
2013 |
|
Biliary Atresia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Common variants of GPC1 gene were genetically involved in BA risk.
|
27373597 |
2016 |
|
Biliary Atresia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
We observed a statistically significant increase in deletions at 2q37.3 in patients with BA that resulted in deletion of one copy of GPC1, which encodes glypican 1, a heparan sulfate proteoglycan that regulates Hedgehog signaling and inflammation.
|
23336978 |
2013 |
|
Borderline Personality Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Various levels of GPC1-positive and GP2/GPC1-positive EVs were detected in PDAC patients but were not significantly higher than benign pancreatic disease (BPD) patients.
|
30800217 |
2019 |